Last update 01 Nov 2024

CD99

Last update 01 Nov 2024

Basic Info

Synonyms

12E7, CD99, CD99 antigen

+ [7]

Introduction

Involved in T-cell adhesion processes and in spontaneous rosette formation with erythrocytes. Plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1. Involved in T-cell adhesion processes (By similarity).

Drugs associated with CD99

CD99 CAR-T therapy(Bio-Raid)

Target

CD99

Mechanism

CD99 inhibitors

Active Org.

Wuhan Bio-Raid Biotechnology Co., Ltd.

Originator Org.

Wuhan Bio-Raid Biotechnology Co., Ltd.

Active Indication

CD99 positive osteosarcoma [+1]

Inactive Indication-

Drug Highest PhaseIND Approval

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Antibody-conjugated irinotecan liposomal nanoparticle (NanoValent Pharmaceuticals)

Target

CD99 x TOP1

Mechanism

CD99 inhibitors [+1]

Active Org.

NanoValent Pharmaceuticals, Inc.

Originator Org.

NanoValent Pharmaceuticals, Inc.

Active Indication

Glioblastoma Multiforme [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

BK60106

Target

CD99

Mechanism

CD99 inhibitors

Active Org.

Georgetown University Hospital

Originator Org.

Georgetown University Hospital

Active Indication

Ewing Sarcoma

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with CD99

100 Translational Medicine associated with CD99

0 Patents (Medical) associated with CD99

2,323

Literatures (Medical) associated with CD99

18 Dec 2024·Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus].

Article

Author: Qiu, Min ; Zhang, Qianjin ; Wang, Guoliang ; Zhang, Shudong ; Tian, Maofeng ; Wang, Binshuai ; Lu, Min ; Tian, Xiaojun ; Liu, Lei

OBJECTIVETo review and analyze the clinical diagnosis and treatment of renal Ewing's sarcoma with venous tumor embolus, to follow up the survival and prognosis of the patients, and to provide help for the diagnosis and treatment of the disease.METHODSClinical data (including general data, surgical data and postoperative pathological data) of patients diagnosed with renal Ewing's sarcoma with venous tumor embolus in Peking University Third Hospital from June 2016 to June 2022 were collected, and the prognosis of the patients was followed up to analyze the influence of diagnosis and treatment process on the prognosis of the disease.RESULTSThere were 6 patients, including 1 male and 5 females. There were 4 cases of left renal tumor and 2 cases of right renal tumor. The median age at diagnosis was 28 years (16-52 years). The imaging findings were all exogenous tumors with internal necrotic tissue and hemorrhage. The mean maximum tumor diameter was 12.6 cm, and the mean tumor thrombus length was 7.8 cm. Four patients underwent open surgery and 2 patients underwent laparoscopic surgery. The postoperative pathological results were renal Ewing sarcoma. Immunohistochemical results showed 3 cases of CD99 (+), 2 cases of FLI-1 (+), and 1 case of CD99, FLI-1 (-). 3 patients received chemotherapy (cyclophosphamide, doxorubicin, vincristine/ifosfamide, etoposide), 1 case received chemotherapy combined with radiotherapy, and 2 cases received no adjuvant therapy. The mean overall survival (OS) of the 6 patients was 37 months, and the mean OS of the 4 patients (47 months) who received chemotherapy was significantly higher than that of the 2 patients (16 months) who did not receive chemotherapy (P=0.031).CONCLUSIONRenal Ewing's sarcoma with venous tumor embolus is rare in clinic, and it is common in young female patients. The operation is difficult and the prognosis is poor. Surgical resection, adjuvant radiotherapy and chemotherapy can improve the overall survival rate of the patients.

01 Nov 2024·International Journal of Gynecological Pathology

A Novel EPC1::KDM2B Fusion in High-grade Endometrial Stromal Sarcoma

Article

Author: Vroobel, Katherine M. ; Khalid, Sana ; Attygalle, Ayoma D. ; Cavalchini, Silvia

The spectrum of endometrial stromal sarcoma (ESS) has expanded substantially since the publication of the most recent World Health Organisation (WHO) Classification of Female Genital Tumours and the advent of widely available genomic testing. We describe a uterine mesenchymal tumor harboring a novel EPC1::KDM2B fusion, best classified within the umbrella of high-grade endometrial stromal sarcoma (HGESS). This tumor was composed of a uniform population of spindled cells with some myxoid stroma, a mitotic rate of up to 21/10 high-power fields, and a largely pushing margin with focal vascular invasion. Immunohistochemistry showed strong and diffuse cyclin D1 positivity while CD10, WT1, DOG1, CD117, CD34, CD99, S100, MelanA, SMA, desmin, and h-caldesmon were negative. The tumor was confined to the uterus and no recurrence has been detected thus far, albeit with a short follow-up interval of 9 mo.

01 Nov 2024·Drug Development Research

RNA sequencing comparing centenarian and middle‐aged women lymphoblastoid cell lines identifies age‐related dysregulated expression of genes encoding selenoproteins, heat shock proteins, CD99, and BID

Article

Author: Goldenberg‐Bogner, Ofir ; Israel‐Elgali, Ifat ; Shomron, Noam ; Volkov, Hadas ; Voinsky, Irena ; Puzianowska‐Kuźnicka, Monika ; Gurwitz, David

AbstractWomen typically live longer than men, and constitute the majority of centenarians. We applied RNA‐sequencing (RNA‐seq) of blood‐derived lymphoblastoid cell lines (LCLs) from women aged 60‐80 years and centenarians (100‐105 years), validated the RNA‐seq findings by real‐time PCR, and additionally measured the differentially expressed genes in LCLs from young women aged 20‐35 years. Top RNA‐seq genes with differential expression between the age groups included three selenoproteins (GPX1, SELENOW, SELENOH) and three heat shock proteins (HSPA6, HSPA1A, HSPA1B), with the highest expression in LCLs from young women, indicating that young women are better protected from oxidative stress. The expression of two additional genes, BID encoding BH3‐interacting domain death agonist and CD99 encoding CD99 antigen, showed unique age dependence, with similar expression levels in young and centenarian women while exhibiting higher and lower expression levels, respectively, in LCLs from women aged 60‐80 years compared with the two other age groups. This age‐related differential expression of BID and CD99 suggests elevated inflammation susceptibility in middle‐aged women compared with either young or centenarian women. Our findings, once validated with human peripheral blood mononuclear cells and further cell types, may lead to novel healthy aging diagnostics and therapeutics.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CD99

Basic Info

Related

Analysis